clozapine should only be given to schizophrenic
patients who have not responded adequately to
antipsychotics other than clozapine. Clozapine may
also be given to schizophrenic patients who are at risk
of suicide or violence against themselves or others
(Rafizadeh et al., 20-23; Soiza et al., 2018).
8 CONCLUSIONS
Patients on typical antipsychotic therapy
experienced more extrapyramidal syndrome side
effects than patients on atypical antipsychotic
therapy. However, the side effects of atypical
antipsychotics were found to be more dangerous,
with a risk of death due to the metabolic syndrome
side effects they cause.
REFERENCES
Azimi Manavi, B., Stuart, A. L., Pasco, J. A., Hodge, J. M.,
Weerasinghe, D. K., Samarasinghe, R. M., & Williams,
L. J. (2023). Antipsychotic medication use and fracture:
a case–control study. Scientific Reports, 13(1), 1–7.
https://doi.org/10.1038/s41598-023-40762-w
de Boer, J. N., Brand, B. A., & Sommer, I. E. C. (2023).
Antipsychotica voor vrouwen: overzicht van de
literatuur en praktijkadviezen. Tijdschrift Voor
Psychiatrie, 65(2), 87–94.
Doane, M. J., Sajatovic, M., Weiden, P. J., O’Sullivan, A.
K., Maher, S., Bjorner, J. B., Kessler, A. S., Carpenter-
Conlin, J., Bessonova, L., & Velligan, D. I. (2020).
Antipsychotic treatment experiences of people with
schizophrenia: Patient perspectives from an online
survey. Patient Preference and Adherence, 14, 2043–
2054. https://doi.org/10.2147/PPA.S270020
Haafizah Dania, Melisa I. Barliana, D. A. P., & Abdulah,
R. (2019). Effect of Atypical Antipsychotic on Blood
Pressure in Inpatients with Schizophrenia of Prof. Dr.
Soerojo Mental Health Hospital Magelang. Journal of
Pharmacy and Bioallied Sciences. https://doi.org/10.41
03/jpbs.JPBS_211_19
Haddad, C., Salameh, P., Sacre, H., Clément, J. P., &
Calvet, B. (2023). Effects of antipsychotic and
anticholinergic medications on cognition in chronic
patients with schizophrenia. BMC Psychiatry, 23(1), 1–
13. https://doi.org/10.1186/s12888-023-04552-y
Handayani, D. S., Cahaya, N., & Srikartika, V. M. (2017).
Pengaruh Pemberian Kombinasi Antipsikotik Terhadap
Efek Samping Sindrom Ekstrapiramidal Pada Pasien
Skizofrnia di Rumah Sakit Jiwa Sambang Lihum.
Farmaka, 15(3), 86–95. https://scholar.archive.org/
work/2kfmygr42jg7hehlujj6aaykta/access/wayback/htt
p://jurnal.unpad.ac.id/farmaka/article/viewFile/13324/
pdf
Hirigo, A. T., Teshome, T., Abera Gitore, W., & Worku, E.
(2021). Prevalence and Associated Factors of
Dyslipidemia Among Psychiatric Patients on
Antipsychotic Treatment at Hawassa University
Comprehensive Specialized Hospital. Nutrition and
Metabolic Insights, 14. https://doi.org/10.1177/11786
388211016842
Jia, N., Li, Z., Li, X., Jin, M., Liu, Y., Cui, X., Hu, G., Liu,
Y., He, Y., & Yu, Q. (2022). Long-term effects of
antipsychotics on mortality in patients with
schizophrenia: a systematic review and meta-analysis.
Brazilian Journal of Psychiatry, 44(6), 664–673.
https://doi.org/10.47626/1516-4446-2021-2306
Julaeha, J., Athiyah, U., & Hermansyah, A. (2020). The
prescription patterns of second-generation
antipsychotics in schizophrenia outpatient setting.
Journal of Basic and Clinical Physiology and
Pharmacology, 30(6), 1–5. https://doi.org/10.1515/
jbcpp-2019-0289
Julaeha, J., Athiyah, U. M. I., Yuliana, V., Ayuningtyas, J.
P., & Hermansyah, A. (2021). Schizophrenia,
Metabolic Syndrome and the Opportunity for
Developing Pharmacist-led Toolkit for Education and
Metabolic Syndrome Screening (EMESYS): A Review.
International Journal of Pharmaceutical Research
,
13(02), 3407–3413. https://doi.org/10.31838/ijpr/20
21.13.02.154
Kementrian Kesehatan RI. (2018). Profil Kesehatan
Indonesia 2018. In M. K. drg. Rudy Kurniawan, M. S.
Yudianto, SKM, M. Boga Hardhana, S.Si, & M. K.
Tanti Siswanti, SKM (Eds.), Health Statistics.
https://www.kemkes.go.id/downloads/resources/downl
oad/pusdatin/profil-kesehatan-indonesia/profil-
kesehatan-indonesia-2018.pdf
Lähteenvuo, M., & Tiihonen, J. (2021). Antipsychotic
Polypharmacy for the Management of Schizophrenia:
Evidence and Recommendations. Drugs, 81(11), 1273–
1284. https://doi.org/10.1007/s40265-021-01556-4
Li, X., Zhou, W., & Yi, Z. (2022). A glimpse of gender
differences in schizophrenia. General Psychiatry,
35(4), 2–4. https://doi.org/10.1136/gpsych-2022-1008
23
Meyer, J. M., & Correll, C. U. (2023). Increased Metabolic
Potential, Efficacy, and Safety of Emerging Treatments
in Schizophrenia. CNS Drugs, 37(7), 545–570.
https://doi.org/10.1007/s40263-023-01022-7
Neill, E., Rossell, S. L., Yolland, C., Meyer, D., Galletly,
C., Harris, A., Siskind, D., Berk, M., Bozaoglu, K.,
Dark, F., Dean, O. M., Francis, P. S., Liu, D., Phillipou,
A., Sarris, J., & Castle, D. J. (2022). N-Acetylcysteine
(NAC) in Schizophrenia Resistant to Clozapine: A
Double-Blind, Randomized, Placebo-Controlled Trial
Targeting Negative Symptoms. Schizophrenia Bulletin,
48(6), 1263–1272. https://doi.org/10.1093/schbul/
sbac065
Organization, W. H. (2022). Schizophrenia. Who. Int.
https://www.who.int/news-room/fact-
sheets/detail/schizophrenia
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew,
N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C.